The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Evolution of autoSCT in multiple myeloma: patient demographics and improved outcomes
Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating trends in outcomes for patients with multiple myeloma who have received autologous stem cell transplantation (autoSCT) since 1988. The study included over 3000 patients and showed that the median age for autoSCT had increased over time, as had the number of patients with higher-risk cytogenetics and pre-existing co-morbidities receiving autoSCT. Improvements to induction therapy and maintenance therapy contributed to improved outcomes, including progression-free survival (PFS) and overall survival (OS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: Bioline
Research Funding: Amgen, Janssen, Angiocrine, NexImmune
